pharma · Advanced Solid Tumor · Acute Myeloid Leukemia or Myelodysplastic Syndromes · APRE
Aprea Therapeutics
Aprea Therapeutics is a pharma organization headquartered in Doylestown, USA. It trades on NYSE under ticker APRE. Primary therapeutic focus areas include Advanced Solid Tumor, Acute Myeloid Leukemia or Myelodysplastic S
3805 Old Easton Rd, Doylestown, Pennsylvania 18902, US HQ
15 Employees
Public company Type
APRE · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3805 Old Easton Rd, Doylestown, Pennsylvania 18902, US
- Employees
- 15
- Programs
- 15
- Drugs
- 5
- Patents
- 6
APR-246 (eprenetapopt) + Pembrolizumab
Phase 2 · small molecule · Bladder Cancer
APR-246 (eprenetapopt) + Pembrolizumab for Bladder Cancer is a Phase 2 program (small_molecule) at Aprea Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code A20-11195
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Aprea Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Bladder Cancer
- Status
- completed
- Trials
- 1